Name:
EMPEROR: Reduced Trial
Description:
EMPEROR: Reduced Trial
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/c17a269e-5819-471d-a436-e9d47235198a/thumbnails/c17a269e-5819-471d-a436-e9d47235198a.jpeg?sv=2019-02-02&sr=c&sig=dlQmekeKoEzvRYrPzL7vZofQQ3492ccevOa3qtb4B5E%3D&st=2024-12-22T05%3A07%3A44Z&se=2024-12-22T09%3A12%3A44Z&sp=r
Duration:
T00H03M30S
Embed URL:
https://stream.cadmore.media/player/c17a269e-5819-471d-a436-e9d47235198a
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/c17a269e-5819-471d-a436-e9d47235198a/18778960.mp3?sv=2019-02-02&sr=c&sig=0TEMd0eKaj3OJYY9K3jggjRQ28RI4rhIN5Rmgo%2B6KRg%3D&st=2024-12-22T05%3A07%3A44Z&se=2024-12-22T07%3A12%3A44Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's, The Heart Board Review, and other online resources available only through accesscardiology.com. [ Music ] >> A prior trial reported the results of the SGLT2 medication, Dapagliflozin, in heart failure with a reduced ejection fraction. Some of the prior early studies suggested that there was a very positive effect that could be seen with another agent, Empagliflozin. [ Music ] Hi, Dr. Bernie here, and welcome to Practice Impact Extra.
The DAPA Heart Failure Trial was presented in March 2020 and demonstrated a benefit of the diabetic medication Dapagliflozin in patients with heart failure and a reduced ejection fraction. This SGLT2 medication was effective in both diabetic and non-diabetic. At the European Society of Cardiology meeting in August 2020, the EMPEROR-Reduced Trial was presented.
This trial was designed with the goal to assess the safety and efficacy of Empagliflozin in the patient with symptomatic heart failure with reduced ejection fraction, irrespective of their diabetic status. 3,730 patients were randomized either to Empagliflozin 10 milligrams or a matching placebo. All patients were receiving appropriate guideline directed medical therapy for heart failure.
Patients had chronic heart failure and had a reduced ejection fraction of less than 40%. Indeed, the mean ejection fraction of the group was 27%. The follow up of this trial was 16 months. So what were the principal findings? Cardiovascular death or heart failure hospitalizations were significantly reduced, 19% for the impact group versus 24% in the placebo arm. This was primarily driven by a decrease in heart failure hospitalization.
Secondary outcomes, total hospitalization and composite real outcome were all significantly reduced. So what can we see with their conclusion? Among patients receiving recommended therapy, those in the Empagliflozin groups had a lower risk of cardiovascular death and hospitalization than those in the placebo group, regardless of the presence or absence of diabetes mellitus. So what do I think?
I think this is really not a diabetes story, but an assessment of a new class of cardiac medication to treat symptomatic heart failure and reduced ejection fraction. As a cardiologist, I think it's time for all of us to get on board. Thank you for joining me and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features.
To subscribe or learn more, please visit accesscardiology.com.
